What tesamorelin is

Tesamorelin is a synthetic analog of growth hormone releasing hormone (GHRH), the peptide the hypothalamus produces to signal the pituitary gland to secrete growth hormone (GH). Unlike sermorelin, which replicates only the first 29 amino acids of GHRH, tesamorelin carries the full 44-amino acid sequence of endogenous GHRH. It is chemically modified with a trans-3-hexenoic acid group attached to the N-terminus, which increases the compound's stability and slows its degradation by plasma proteases compared to native GHRH.

The result of that modification is a longer effective half-life in circulation and more sustained GHRH receptor stimulation, which produces more prolonged GH pulses than shorter GHRH analogs. Like all GHRH analogs, tesamorelin works upstream of GH itself: it asks the pituitary to produce and release its own GH rather than delivering exogenous GH directly. That distinction matters pharmacologically. The pituitary's own regulatory feedback mechanisms, including somatostatin-mediated inhibition, remain active when a GHRH analog drives GH release. Whether that characteristic translates into meaningful clinical differences compared to exogenous GH in adults has not been established by large controlled trials outside the approved indication.

Regulatory status — read carefully

Tesamorelin is FDA-approved. The approval is narrow. Both facts matter.

In 2010, the FDA approved tesamorelin acetate under the brand name Egrifta (manufactured by Theratechnologies) for the treatment of excess visceral abdominal fat in HIV-positive adults receiving antiretroviral therapy, a condition called HIV-associated lipodystrophy. The approval was based on two Phase III randomized, placebo-controlled trials involving roughly 800 HIV-positive patients, with CT-measured visceral adipose tissue as the primary endpoint. A second-generation formulation, Egrifta SV, received FDA approval in 2019 and does not require refrigeration. The approval covers that one indication and that population only. Tesamorelin is not FDA-approved for body composition optimization, visceral fat reduction in people without HIV, GH axis enhancement, or any of the uses most commonly discussed online. Those uses are off-label at best and, when sold as research compounds without a prescription, exist in a distinct and less regulated category. Tesamorelin is currently sold in three forms: as brand-name Egrifta or Egrifta SV (prescription drug, approved indication), as compounded tesamorelin (requires a physician prescription through a licensed pharmacy), and as research-labeled tesamorelin (not for human use label, sold without a prescription). These are not equivalent categories.

That distinction between "FDA-approved drug" and "research compound sold under the same name" is worth sitting with. The existence of an approval for Egrifta does not lend regulatory or safety legitimacy to research-labeled tesamorelin sold by vendors without a prescription. The approval was granted for a specific pharmaceutical product, manufactured to pharmaceutical standards, tested in a specific patient population, for a specific indication. Research compounds operate under entirely different standards, or none.

How tesamorelin is discussed and marketed

Online marketing and community discussion around tesamorelin centers on four main areas: visceral fat reduction, general body composition, GH axis optimization, and cognitive function. Here is how each maps to the actual evidence base.

Area 1

Visceral fat reduction

This is the one area with robust clinical trial data, but the data comes entirely from the HIV-positive population studied in the Egrifta approval trials. Those trials documented meaningful reductions in CT-measured visceral adipose tissue. Extrapolating those results to metabolically healthy adults without HIV-associated lipodystrophy requires data that does not exist at the same scale.

Robust (approved indication only)
Area 2

General body composition

Marketing frequently positions tesamorelin as a body composition compound for lean mass preservation or fat reduction outside the HIV context. The data here is thin. Small studies in non-HIV populations have measured GH and IGF-1 changes, but controlled evidence linking those changes to body composition outcomes in healthy adults is limited.

Limited human data
Area 3

GH axis stimulation

The pharmacological mechanism is established. Tesamorelin stimulates pulsatile GH release via GHRH receptor agonism. GH and IGF-1 increases following tesamorelin administration have been measured in both HIV-positive and small non-HIV trials. The clinical significance of those changes for healthy adults seeking GH optimization has not been established in large controlled trials.

Limited human data
Area 4

Cognitive function

Some research groups have investigated tesamorelin's effects on cognition, particularly in older adults, given the known relationship between GH axis activity and neurological function. Preliminary data from smaller trials is interesting but not conclusive. This remains an active research area; clinical recommendations are not supported by the current evidence base.

Emerging / preliminary

The pattern across these areas is the same one that runs through most peptide marketing: the mechanistic story is real and the approved-indication evidence is legitimate, but the gap between that and the broader claims vendors make is substantial. Knowing that tesamorelin has an FDA approval can create a false sense of confidence about uses that were never evaluated in the approval process.

One important informational note on dosing context: the Egrifta label specifies the dose and administration approach for the approved HIV-lipodystrophy indication. That published information exists in the FDA prescribing information and is publicly accessible. This page does not reproduce it as a protocol because any use outside the approved indication requires evaluation and guidance from a qualified healthcare provider. This article is informational, not a protocol.

How to evaluate a vendor selling tesamorelin

Tesamorelin is available as a prescription drug (Egrifta, Egrifta SV) through standard pharmaceutical channels. What the research vendor market sells is a different category entirely. If you are encountering tesamorelin sold without a prescription as a research compound, the following checklist applies. It also applies to compounded formulations, where additional pharmacy-level verification matters.

Vendor evaluation checklist

  • Third-party COA from an accredited lab: The certificate of analysis should come from a laboratory independent of the vendor, carrying ISO 17025 accreditation or equivalent. The lab name, accreditation number, and contact should all be publicly verifiable. A COA that cannot be traced to a real accredited lab is not a meaningful quality assurance document.
  • Batch traceability: The COA should reference the specific batch number on the product you receive. Generic or undated COAs that are not tied to a batch offer no assurance about the specific vial you purchase.
  • Purity and identity confirmation: Look for HPLC purity data (ideally above 98%) alongside mass spectrometry or amino acid sequencing that confirms the peptide's identity. Purity alone by a single method is insufficient for a 44-amino acid compound where sequence integrity matters.
  • Claims review: A vendor making treatment, outcome, or curative claims about tesamorelin outside the approved HIV-lipodystrophy context is marketing beyond the legal scope of research compounds. Strong efficacy claims in a research vendor context are a signal worth noting, not a feature.
  • Compounding vs. research labeling: Compounded tesamorelin is a pharmaceutical product that requires a valid physician prescription and a licensed compounding pharmacy. Research-labeled tesamorelin sold without a prescription is a different regulatory category. Understanding which you are purchasing is relevant both legally and for quality expectations.
  • Business transparency: Reputable research vendors provide verifiable contact information, a physical business address, and a clear process for batch verification inquiries. Anonymous or difficult-to-contact vendors offer limited recourse if product quality is in question.

Affiliate disclosure: The link below is a paid affiliate relationship. We earn a commission if you purchase through it. This relationship did not influence our evaluation of tesamorelin or the vendor criteria above. See our full disclosure policy.

Looking for a vendor that meets these criteria?

We reviewed vendors against the checklist above. The following link goes to a vendor whose COA documentation and batch traceability we found consistent with the standards described in this article. We have not evaluated the product itself, and this is not a clinical recommendation.

View vendor COA documentation Affiliate link

Tesamorelin belongs to the GHRH analog class. The compounds most often discussed in the same context share the same mechanism, GHRH receptor agonism, but differ in structure, half-life, evidence base, and regulatory status.

Sermorelin

A 29-amino acid GHRH analog that was FDA-approved as Geref for pediatric GH deficiency and subsequently withdrawn from the market around 2008. No current approval. Shorter half-life than tesamorelin. Now sold compounded or as a research compound.

Read Sermorelin explainer →
CJC-1295

A modified GHRH analog engineered for an extended half-life through albumin binding. Never held an FDA approval. Small human studies exist. Research compound only; regulatory status is distinct from tesamorelin.

Read CJC-1295 explainer →
Ipamorelin

A growth hormone secretagogue that works through the ghrelin receptor rather than GHRH receptors. Different mechanism from tesamorelin; sometimes combined with GHRH analogs. Preclinical-dominant evidence base; limited human data.

Read Ipamorelin explainer →

Sources

  1. 1 Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370. PubMed
  2. 2 Falutz J, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled Phase 3 trials with safety extension data. J Acquir Immune Defic Syndr. 2010;53(3):311-322. PubMed
  3. 3 FDA. Egrifta (tesamorelin for injection) prescribing information. NDA 022505. Theratechnologies. FDA.gov
  4. 4 Stanley TL, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2012;308(14):1455-1462. PubMed
  5. 5 Clemmons DR. Consensus statement on the standardization and evaluation of growth hormone and insulin-like growth factor assays. Clin Chem. 2011;57(4):555-559. PubMed
  6. 6 Bhutani S, et al. Tesamorelin reduces liver fat in HIV-infected men with visceral adiposity. AIDS. 2012;26(16):2055-2062. PubMed
  7. 7 Baker LD, et al. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults. Arch Neurol. 2012;69(11):1420-1429. PubMed
  8. 8 Veldhuis JD, Bowers CY. Human GH pulsatility: an ensemble property regulated by age and gender. J Endocrinol Invest. 2003;26(9):799-813. PubMed
  9. 9 FDA. Human drug compounding. Regulatory information on section 503A and 503B compounding. FDA.gov
  10. 10 Spooner LM, Olin JL. Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy. Ann Pharmacother. 2012;46(2):240-247. PubMed

Frequently asked questions

Is tesamorelin FDA-approved?
Yes, but for one specific indication. Tesamorelin is FDA-approved as Egrifta (and Egrifta SV) for the treatment of excess visceral abdominal fat in HIV-positive adults receiving antiretroviral therapy, a condition called HIV-associated lipodystrophy. That approval was granted in 2010 based on Phase III randomized controlled trial data in that specific patient population. Tesamorelin is not FDA-approved for body composition optimization, fat reduction in people without HIV, GH axis enhancement, or other uses commonly discussed online. Those uses are outside the approved scope, and the research-labeled versions of tesamorelin sold without a prescription are not cleared for human use regardless of any approval that exists for the pharmaceutical product.
How does tesamorelin differ from sermorelin?
Both are GHRH analogs that stimulate pituitary GH release by binding GHRH receptors, but they differ in structure, half-life, and regulatory history. Sermorelin replicates only the first 29 amino acids of endogenous GHRH. Tesamorelin carries the full 44-amino acid GHRH sequence plus a chemical modification that slows its breakdown in the bloodstream, producing a longer half-life and more sustained GH stimulation. On the regulatory side, sermorelin held an FDA approval that was voluntarily withdrawn around 2008 and no longer has any current approval. Tesamorelin holds an active FDA approval, though only for the HIV-lipodystrophy indication. Both are currently sold as compounded or research compounds for uses outside any approved scope.
What does the evidence actually show for tesamorelin and visceral fat?
The strongest evidence for tesamorelin and visceral fat reduction comes from the two Phase III trials that formed the basis of the Egrifta FDA approval. In those trials, HIV-positive adults with lipodystrophy who received tesamorelin showed statistically significant reductions in CT-measured visceral adipose tissue compared to placebo. Those are legitimate, well-designed trials with a meaningful patient population. The limitation is that those results apply to HIV-positive patients with lipodystrophy, a condition involving abnormal fat redistribution associated with antiretroviral therapy. Extrapolating those results to metabolically healthy adults seeking fat reduction or body composition improvement requires evidence that does not currently exist at comparable scale or rigor. Smaller studies outside the HIV population have measured GH and body composition changes, but they do not match the scale or regulatory quality of the approval trials.
Can tesamorelin be legally obtained without a prescription?
The brand-name Egrifta and Egrifta SV require a valid physician prescription and are dispensed through standard pharmaceutical channels for the approved indication. Compounded tesamorelin also requires a valid prescription from a licensed healthcare provider and must be dispensed by a licensed compounding pharmacy under federal compounding regulations. Research-labeled tesamorelin is sold by some vendors without a prescription under a "not for human use" label. That category occupies a different and less clearly regulated position than prescription pharmaceuticals. The legal landscape around research peptides is complex, actively evolving, and jurisdiction-dependent. If you are considering tesamorelin for any purpose, that conversation starts with a qualified healthcare provider, not a vendor website.